>> Just seems to me that pan-inhibition at our stage of technology, especially for a class of enzymes where we *know* there are distinct players, seems a bit anachronistic.
This is an old drug PFE bought from Idun, first entered clinic more than 10 years ago.
As of history of moving from pan to isoforms, look at PI3K, HDAC for examples.
I would submit that the anachronism you’ve highlighted likely means Emricasan won’t end up being the best drug for liver disease; however, by no means does this imply that Emricasan won’t work (which is what your initial post in this thread seemed to be implying).
If Emricasan merely works in some liver-disease indications, CNAT longs should end up doing quite well, IMO. It is not necessary that Emricasan be best or even second-best among the various drug candidates aimed at (non-HCV/HBV) liver disease.
News 
Market Data 
Discover 
